For research use only. Not for therapeutic Use.
AN3199 is a PDE4 inhibitor with an IC50 of 94.5 nM. AN3199 can be used for the research of inflammation-associated diseases such as asthma and chronic obstructive pulmonary disease (COPD)[1][2].
AN3199 (compound 11) (1 h) disappears (98.0%) is mainly converts to corresponding acid (76.6) in mouse plasma[1].
| Catalog Number | I000672 |
| CAS Number | 1187187-10-5 |
| Synonyms | butyl 6-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]pyridine-3-carboxylate |
| Molecular Formula | C17H18BNO5 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H18BNO5/c1-2-3-8-22-17(20)12-4-7-16(19-10-12)24-14-5-6-15-13(9-14)11-23-18(15)21/h4-7,9-10,21H,2-3,8,11H2,1H3 |
| InChIKey | BJXLLSAUQIAPDB-UHFFFAOYSA-N |
| SMILES | B1(C2=C(CO1)C=C(C=C2)OC3=NC=C(C=C3)C(=O)OCCCC)O |
| Reference | [1]. Zhang YK, et al. Design and synthesis of boron-containing PDE4 inhibitors using soft-drug strategy for potential dermatologic anti-inflammatory application. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2270-4. [2]. Akama Tsutomu, et al. Preparation of boron-containing small molecules as anti-inflammatory agents. From PCT Int. Appl. (2009), WO 2009111676 A2 20090911. |
